Carl Zeiss Meditec (ETR:AFX) Loses Further 8.1% This Week, as Profits Continue to Decline

Carl Zeiss Meditec (ETR:AFX) has lost a further 8.1% in value this week, continuing a trend of declining profits for the company.

The company's share price has fallen from €127.50 at the start of the week to €117.20 by Friday's close, wiping out gains made earlier in the year.

The decline in Carl Zeiss Meditec's share price comes despite the company reporting a slight increase in revenue for the first half of 2023. However, profits declined by 12.5% over the same period, due to rising costs and supply chain disruptions.

The company has been hit by a number of challenges in recent months, including the war in Ukraine and the ongoing COVID-19 pandemic. These factors have disrupted supply chains and led to higher costs, which have impacted the company's profitability.

Analysts believe that the company's share price could continue to decline in the coming months, as the economic outlook remains uncertain. However, they also note that the company's long-term prospects are still positive, due to its strong market position and innovative products.

Key Points:

• Carl Zeiss Meditec (ETR:AFX) has lost a further 8.1% in value this week, continuing a trend of declining profits for the company.
• The company's share price has fallen from €127.50 at the start of the week to €117.20 by Friday's close, wiping out gains made earlier in the year.
• The decline in Carl Zeiss Meditec's share price comes despite the company reporting a slight increase in revenue for the first half of 2023. However, profits declined by 12.5% over the same period, due to rising costs and supply chain disruptions.
• Analysts believe that the company's share price could continue to decline in the coming months, as the economic outlook remains uncertain. However, they also note that the company's long-term prospects are still positive, due to its strong market position and innovative products.